secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001140361-23-014674
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma reports Q4 2022 net income $33.9M, full-year net income $17.9M; cash $42.6M
--------------------------------------------------------------------------------

- Net income $17.9M for 2022 vs net loss $56.7M in 2021; diluted EPS $0.87.
- Revenue $39.9M from Nyxol license agreement with Viatris (upfront $35M).
- Cash $42.6M, no debt, runway into 2025.
- PDUFA date Sept 28, 2023 for Nyxol in reversal of mydriasis; $10M milestone upon approval.
- APX3330 ZETA-1 trial achieved statistical significance on key endpoint; End-of-Phase 2 meeting planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/0001140361-23-014674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036123014674/brhc10050620_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-014674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer